文献速递消化道肿瘤放疗姑息放疗与转移瘤

食管T1a-MM/T1b-SM1鳞癌ESD后追加放疗改善局部区域控制

Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control.
PubMed 文献 · Radiat Oncol · 2018-01-29

追加放疗组3年局部区域控制率显著优于未放疗组(100% vs 57.8%,p=0.022),但总生存与病因特异生存无显著差异;ESD后黏膜缺损≥3/4周径者放疗组局部控制更优,但6例中2例出现治疗相关食管狭窄。

要点

  • ESD后追加放疗可显著改善T1a-MM/T1b-SM1食管鳞癌的3年局部区域控制。
  • 追加放疗未显著改善总生存与病因特异生存。
  • ESD后黏膜缺损≥3/4周径者放疗需谨慎,可能增加食管狭窄风险。

核心结论

  • ESD后追加放疗有助于改善pT1a-MM和pT1b-SM1食管鳞癌的局部区域控制。
  • 追加放疗未显著改善总生存与病因特异生存。
  • ESD后黏膜缺损较大者追加放疗需权衡局部控制获益与食管狭窄风险。

研究设计与样本

  • 评估局部区域控制、总生存、病因特异生存及包括治疗相关食管狭窄在内的不良事件。

主要发现

  • RT组3年局部区域控制率显著优于non-RT组(100% vs 57.8%,p=0.022)。
  • ESD后化疗未改善局部区域控制。
  • 多因素分析显示放疗是局部区域控制更佳的独立预后因素(p=0.0022)。
  • RT组与non-RT组的总生存和病因特异生存无显著差异。
  • ESD后黏膜缺损≥3/4食管周径者中,RT组局部区域控制优于non-RT组(p=0.049)。

关键数值与推荐

  • RT组3年局部区域控制率为100%,non-RT组为57.8%(p=0.022)。
  • 多因素分析中放疗对局部区域控制的p=0.0022。
  • 黏膜缺损≥3/4周径亚组中RT组与non-RT组局部区域控制比较p=0.049。
  • RT组6例ESD后大黏膜缺损患者中2例出现治疗相关食管狭窄。
  • ESD后黏膜缺损小于3/4周径者未出现治疗相关狭窄。

临床怎么用

  • 对T1a-MM/T1b-SM1食管鳞癌ESD后患者,可考虑追加放疗以改善局部区域控制。
  • 追加放疗前应评估ESD后黏膜缺损范围,大缺损者需谨慎权衡食管狭窄风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic submucosal dissection (ESD) can be used as a less invasive treatment option for superficial esophageal cancer involving the muscularis mucosae (T1a-MM) or upper third of the submucosa (T1b-SM1). Additional treatment after ESD is needed to prevent lymph node metastasis. However, the efficacy of radiotherapy following ESD has not been well evaluated. Moreover, the clinical outcomes of patients with large mucosal defects of the esophagus who received radiotherapy after ESD have not been reported. This study aimed to clarify the efficacy of additional radiotherapy following ESD for esophageal squamous cell cancer involving T1a-MM or T1b-SM1. METHODS: We analyzed twenty-seven patients with pathologically confirmed T1a-MM or T1b-SM1 esophageal squamous cell cancer treated by ESD. Thirteen patients received additional radiotherapy (RT group), and the remaining patients did not (non-RT group). Locoregional control (LRC), overall survival, cause-specific survival, and adverse events including treatment-related esophageal strictures were evaluated. RESULTS: The three-year LRC was significantly better for the RT than the non-RT group (100% vs. 57.8%, respectively; p = 0.022). Chemotherapy following ESD did not improve LRC. Multivariate analysis showed that radiotherapy was an independent prognostic factor for better LRC (p = 0.0022). Contrary to the results in LRC, overall and cause-specific survival were not significantly different between the RT and non-RT groups. A subgroup analysis of patients with mucosal defects involving ≥ 3/4 of the esophageal circumference after ESD showed that LRC of the RT group was better than that of the non-RT group (p = 0.049). Treatment-related esophageal strictures were observed in 2 of 6 patients in the RT group with large mucosal defects after ESD. No patients with mucosal defects involving less than 3/4 of the circumference after ESD developed treatment-related strictures. CONCLUSIONS: Radiotherapy after ESD contributed to better LRC in esophageal squamous cell cancer involving pT1a-MM and pT1b-SM1. Esophageal strictures were observed in some patients with large mucosal defects after ESD. Despite leading to better LRC, radiotherapy after ESD should be undertaken after careful consideration for patients with large mucosal defects after ESD.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hisano O, Nonoshita T, Hirata H, et al. Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. Radiat Oncol. 2018. PMID: 29378603. doi:10.1186/s13014-018-0960-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。